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THE EFFECT OF PULSED ELECTROMAGNETIC FIELDS ON
PHYSICAL FUNCTION MEASURED BY WOMAC
OSTEOARTHRITIS INDEX IN PATIENTS WITH KNEE
OSTEOARTHRITIS -A PILOT STUDY
T. Nemcic, S. Grazio, F. Grubisic, V. Matijevic, H. Skala
Sestre Milosrdnice Univ. Hosp., Zagreb, Croatia
Purpose: The aim of our study was to asses the effect of pulsed
electromagnetic ﬁelds (PEMFs) on physical function measured by
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) in patients with knee osteoarthritis (OA) through a
single-blind placebo controlled clinical study.
Methods: Fifty-six consecutive patients, aged 60.62±8.81 years,
presenting to Outpatient Clinic of the Department of Rheuma-
tology, Physical Medicine and rehabilitation, Sestre Milosrdnice
University Hospital in Zagreb (Croatia) were included in this study.
They met the criteria of the American College of Rheumatology
(ACR) for the deﬁnition and classiﬁcation of knee OA. Patients
ought to have experienced knee pain for at least 14 days in the
past 30 days before the beginning of the study, with pain intensity
above 30 mm on the 100 mm visual analogue scale (VAS) and
Kellgren-Lawrence scale grade 2 or 3 on x-ray. Average duration
of the symptoms was 10.57±17.64 months. During the study, the
patients were allowed to be on a steady dose of pain-killers and/or
non-steroidal anti-inﬂammatory drugs (NSAIDs) if taken before,
while paracetamol could be used as an escape medication in a
dose up to 2 g per day for not more than 5 consecutive days.
The patients were randomly assigned into two groups: therapeutic
group in which PEMF was administered (intensity 6 mT; frequency
12 Hz) and placebo group where the machine was turned off. Each
patient received a total of 20 treatments that were administered for
30 minutes on 5 week days (with a weekend break). In addition,
all patients were performing isometric exercises for quadriceps
muscle strengthening, on daily basis. Symptoms of knee OA were
assessed by the WOMAC OA Index, a questionnaire addressing
severity of joint pain (5 questions), stiffness (2 questions) and
limitation of physical function (17 questions). Patients fulﬁlled the
questionnaire before the therapy, at the end of the therapy and
one month after the therapy was ﬁnished. Data were analyzed
by SPSS statistical program version 11.5. Apart from descriptive
statistics, t-test and one-way ANOVA were used. The level of
signiﬁcance was set at p<0.05.
Results: A total of 56 patients completed the study: 33 in the
group that received PEMFs and 23 in the group that received
placebo. There was no signiﬁcant difference between the thera-
peutic and control group regarding age, body mass index (BMI),
duration of symptoms and WOMAC OA Index. In both groups,
there was improvement in WOMAC overall scores at the end of
therapy (therapeutic group: t=2,509, df=32, p<0,01; control group:
t=3,164, df=22, p<0,01) as well as during post-treatment follow-up
(therapeutic group: t=3,384, df=28, p<0,01; control group: t=2,764,
df=22, p<0,01). But, no signiﬁcant difference between the groups
was observed at the end of therapy (F=1,134, df=55, p>0,05) and
during follow-up (F=0,003; df=55, p>0,05). Also, no statistically
signiﬁcant differences between the groups were found in WOMAC
subscales of pain (F=0,458, df=55, p>0,05), stiffness (F=0,083,
df=55, p>0,05) and physical function (F=1,145, df=55, p>0,05).
No adverse side-effects were observed during the administration
of PEMFs.
Conclusions: In our sample of patients with knee OA, PEMFs
showed no effect on improvement in activities of daily living, pain
and stiffness measured by WOMAC OA Index. The study was
limited by its small sample size. Further studies with a larger
number of patients are needed to determine the possible clinical
effect of PEMFs in patients with OA.
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CHANNA STRIATUS EXTRACT SUPPLEMENTATION
SIGNIFICANTLY INCREASED PROTEIN GENE PRODUCT
9.5-IMMUNOREACTIVE NERVE FIBRES COMPARED TO
ZINGIBER OFFICINALE EXTRACT IN COLLAGENASE
INDUCED OSTEAOARTHRITIS
S. Ganabadi
Universiti Putra Malaysia, Serdang, Selangor, Malaysia
Purpose: Channa striatus and Zingiber ofﬁcinale are two natu-
ral remedies that can be useful in treating osteoarthritis. The
aim of this study is to compare the protein gene related
9.5-immunoreactivity in the synovial membrane of collagenase
induced osteoarthritis between Zingiber ofﬁcinale extracts and
Channa striatus extract supplementation.
Methods: Osteoarthritis was induced in 30 adult male Sprague
Dawley rat by an intra-articular injection of 50μl of 4mg/ml collage-
nase into the right stiﬂe joint at D1 and D4. The rats were fed rat
pellet and water ad libitum. The rats were divided into three groups:
i. Group 1 is the control group and received saline, ii. Group 2
received 15ml/kg Channa striatus (CS) extract and iii. Group 3
received 15ml/kg of Zingiber ofﬁcinale (ZO) extract. Channa stria-
tus and Zingiber ofﬁcinale extracts were prepared according to the
methods previously described. The saline and extracts were fed
orally using feeding tube from D7 to D28. At D29 the rats were
sacriﬁced and synovial membrane sample were processed for im-
munohistochemistry. The ﬁxed samples were frozen in isopentane,
cooled in liquid Nitrogen and sectioned at 6μm. The sections were
dehydrated in ethanol, rinsed in 0.1M phosphate buffered saline,
then incubated in primary antisera against PGP 9.5 for 24 hours
at 4°C. Sections were then incubated in secondary antiserum (1
hour) followed by staining using HRP/DAB detection kit (Abcam,
USA).
Results: The density of PGP 9.5-immunoreactive nerve ﬁbres
(IR) in the synovial membrane was improved in the CS and
ZO group. The CS group showed signiﬁcantly highest number
(13.3±0.30) of PGP-IR nerve ﬁbres in the right (induced joint)
synovial membrane followed by the ZO (11.1±0.27) and the control
group (3.0±0.26). However, there were no signiﬁcant differences
between the synovial membranes in the contra-lateral (left) joints
(Table 1). When compared the PGP 9.5-immunoreactivity between
the right and left synovial membrane, there were no signiﬁcant
difference in the CS group but the differences were signiﬁcant in
the ZO and control group.
The IR nerve ﬁbres were abundant in the subintimal layer (Fig. 2)
and in the CS and ZO group these ﬁbres were found to be
penetrating between synoviocytes in the intimal layer (Fig. 1).
These were not found in the control group. Apart from this, the
Figure 1. PGP 9.5 immunoreactive
nerve ﬁbres (arrowheads) in the intimal
layer of synovial membrane from colla-
genase induced osteoarthritis treated
with Channa striatus extract. The
nerve ﬁbres were penetrating between
the synoviocytes (arrows).
Figure 2. PGP 9.5 immunoreactive
nerve ﬁbres (arrowhead) in the subin-
timal layer of synovial membrane
from collagenase induced osteoarthri-
tis treated with Channa striatus extract.
The nerve ﬁbres surround the blood
vessel (arrow).
